Compare Cytokinetics Inc (CYTK) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Cytokinetics Inc trades at $82.35 (market cap $11.12B), while State Street SPDR S&P Homebuilders ETF trades at $108.48. The key difference: Cytokinetics Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | XHB | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $87.26 | $121.36 |
52-Week Low | $33.23 | $94.86 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
XHB trades at $107.07, down 1.42% amid bearish technical signals, with support at $104 and resistance at $110. The ETF faces mixed housing data with declining existing home sales but potential tailwinds from new housing legislation. Key indicators show oversold short-term RSI but strong bearish momentum from ADX.
Outlook is cautious due to high mortgage rates and record home prices pressuring demand, though legislative support for homebuilders offers upside. Risks include interest rate sensitivity and economic slowdowns. Analyst sentiment is neutral with focus on housing market recovery timing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
